Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme

Clinical Cancer Research

Volumn 13, Issue 23, 2007, Pages 7155-7165

  Liu, Chunsheng ^a   Sarkaria, Jann N ^a   Petell, Cory A ^a   Paraskevakou, Georgia ^a   Zollman, Paula J ^a   Schroeder, Mark ^a   Carlson, Brett ^a   Decker, Paul A ^a   Wu, Wenting ^a   James, C David ^b   Russell, Stephen J ^a   Galanis, Evanthia ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYLTHIAZOL 2 YL) 5 (3 CARBOXYMETHOXYPHENYL) 2 (4 SULFOPHENYL) 2H TETRAZOLIUM; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BLOCKING ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CASPASE 8 INHIBITOR; CASPASE 9 INHIBITOR; DNA NUCLEOTIDYLEXOTRANSFERASE; FAS ANTIGEN; FAS LIGAND; GUANINE NUCLEOTIDE BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN H; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME DEGRADATION; FLUORESCENCE ACTIVATED CELL SORTING; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; GROWTH CURVE; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MEASLES VIRUS; MOLECULAR INTERACTION; MOUSE; NICK END LABELING; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TREATMENT OUTCOME; UPREGULATION; VIROGENESIS; WESTERN BLOTTING; XENOGRAFT; XERORADIOGRAPHY;

ANIMALS; BRAIN NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CASPASE 8; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; GLIOBLASTOMA; HUMANS; MEASLES VIRUS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 37249023636     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1306     Document Type: Article

References (57)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
2. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30:907-11.
3. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989;16:1405-9.
4. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 1992;34:463-9.
5. Conrad C, Miller CR, Ji Y, et al. Δ24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 2005;12:284-94.
6. King GD, Curtin JF, Candolfi M, Kroeger K, Lowenstein PR, Castro MG. Gene therapy and targeted toxins for glioma. Curr Gene Ther 2005;5:535-57.
7. Lamb RA, Kolakofsky D. Paramyxoviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, et al, editors. Fields virology. 4th ed. Philadelphia (PA): Lippincott-Raven Publishers; 2001.
8. Phuong LK, Allen C, Peng KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003;63:2462-9.
9. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004;64:4919-26.
10. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002;8:527-31.
11. Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 2006;12:2264-71.
12. Giannini C, Sarkaria JN, Saito A, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neurooncol 2005;7:164-76.
13. Cathomen T, Naim HY, Cattaneo R. Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol 1998;72:1224-34.
14. Patel MI, Tuckerman R, Dong Q. A Pitfall of the 3-(4,5-dimethylthiazol-2- yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay due to evaporation in wells on the edge of a 96 well plate. Biotechnol Lett 2005;27:805-8.
15. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
16. de la Pena L, Burgan WE, Carter DJ, et al. Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol Cancer Ther 2006;5:1504-10.
17. Goel A, Janknecht R. Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem 2004;279:14909-16.
18. Scoltock AB, Cidlowski JA. Activation of intrinsic and extrinsic pathways in apoptotic signaling during UV-C-induced death of Jurkat cells: the role of caspase inhibition. Exp Cell Res 2004;297:212-23.
19. Taimen P, Berghall H, Vainionpaa R, Kallajoki M. NuMA and nuclear lamins are cleaved during viral infection-inhibition of caspase activity prevents cleavage and rescues HeLa cells from measles virus-induced but not from rhinovirus 1B-induced cell death. Virology 2004;320:85-98.
20. Perez EC, Shulzhenko N, Morgun A, et al. Expression of Fas, FasL, soluble Fas mRNA in endomyocardial biopsies of human cardiac allografts. Hum Immun 2006;67:22-6.
21. Lee YB, Nagai A, Kim SU. Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res 2002;69:94-103.
22. Song J, Sapi E, Brown W, et al. Roles of Fas and Fas ligand during mammary gland remodeling. J Clin Invest 2000;106:1209-20.
23. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994;86:441-6.
24. Servet-Delprat C, Vidalain PO, Azocar O, Le Deist F, Fischer A, Rabourdin-Combe C. Consequences of Fas-mediated human dendritic cell apoptosis induced by measles virus. J Virol 2000;74:4387-93.
25. Vuorinen T, Peri P, Vainionpaa R. Measles virus induces apoptosis in uninfected bystander T cells and leads to granzyme B and caspase activation in peripheral bloodmo nonuclear cell cultures. Eur J Clin Invest 2003;33:434-42.
26. Hunter A, Hendrikse A, Renan M, Abratt R. Does the tumor microenvironment influence radiation-induced apoptosis? Apoptosis 2006;11:1727-35.
27. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-94.
28. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338-47.
29. Galanis E, Buckner JC. Diffuse cerebral gliomas in adults. In: Noseworthy JH, editor. Neurological therapeutics: principles and practice. 2nd ed. Abingdon: Informa Healthcare; 2006. p. 832-53.
30. Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989;71:1-9.
31. Allen C, Vongpunsawad S, Nakamura T, et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res 2006;66:11840-50.
32. Paraskevakou G, Allen C, Nakamura T, et al. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol Ther 2007;15:677-86.
33. Suit HD, Zietman A, Tomkinson K, Ramsay J, Gerweck L, Sedlacek R. Radiation response of xenografts of a human squamous cell carcinoma and a glioblastoma multiforme: a progress report. Int J Radiat Oncol Biol Phys 1990;18:365-73.
34. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004;103:1641-6.
35. Mandell RB, Mandell LZ, Link CJ, Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999;59:661-8.
36. Chung SM, Advani SJ, Bradley JD, et al. The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther 2002;9:75-80.
37. Bradley JD, Kataoka Y, Advani S, et al. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res 1999;5:1517-22.
38. Blank SV, Rubin SC, Coukos G, Amin KM, Albelda SM, Molnar-Kimber KL. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum Gene Ther 2002;13:627-39.
39. Stanziale SF, Petrowsky H, Joe JK, et al. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by up-regulating ribonucleotide reductase. Surgery 2002;132:353-9.
40. Portella G, Pacelli R, Libertini S, et al. ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2003;88:5027-32.
41. Chen Y, DeWeese T, Dilley J, et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 2001;61:5453-60.
42. Lamfers ML, Grill J, Dirven CM, et al. Potential of the conditionally replicative adenovirus Ad5-24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002;62:5736-42.
43. Geoerger B, Grill J, Opolon P, et al. Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br J Cancer 2003;89:577-84.
44. Mezhir JJ, Advani SJ, Smith KD, et al. Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. Cancer Res 2005;65:9479-84.
45. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999;17:331-67.
46. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8.
47. Lenardo M, Chan KM, Hornung F, et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 1999;17:221-53.
48. Orlinick JR, Vaishnaw A, Elkon KB, Chao MV. Requirement of cysteine-rich repeats of the Fas receptor for binding by the Fas ligand. J Biol Chem 1997;272:28889-94.
49. Starling GC, Bajorath J, Emswiler J, Ledbetter JA, Aruffo A, Kiener PA. Identification of amino acid residues important for ligand binding to Fas. J Exp Med 1997;185:1487-92.
50. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-12.
51. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995;14:5579-88.
52. Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature 1996;384:638-41.
53. Martin DA, Siegel RM, Zheng L, Lenardo MJ. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHα1) death signal. J Biol Chem 1998;273:4345-9.
54. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 1997;22:299-306.
55. Owen-Schaub L, Chan H, Cusack JC, Roth J, Hill LL. Fas and Fas ligand interactions in malignant disease. Int J Oncol 2000;17:5-12.
56. Hasegawa K, Nakamura T, Marks JD, Russell SJ, Peng KW. Effect of ligand binding affinity and receptor density in relation to biology of retargeted viruses [abstract 957]. Mol Ther 2006;13:s369.
57. Myers R, Harvey ME, Greiner SM, et al. Safety of repeat intracerebral administration of MV-CEA in Rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas [abstract 297]. Mol Ther 2006;13:s113.